Skip to content

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01131832
Enrollment
71
Registered
2010-05-27
Start date
2010-09-30
Completion date
2012-02-29
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Keywords

Cholesterol, Plant sterols, Non-response, SNPs,

Brief summary

The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.

Interventions

DIETARY_SUPPLEMENTPlant sterol
DIETARY_SUPPLEMENTPlacebo

Sponsors

University of Manitoba
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* fasting serum LDL cholesterol \>3.0 mmol/L * high or low lathosterol to cholesterol ratio

Exclusion criteria

* smoking * use of lipid lowering therapy * documented cardiovascular/atherosclerotic disease * inflammatory disease * diabetes * uncontrolled hypertension * kidney disease * liver disease * other systemic diseases * cancer * chronic alcohol consumption (\> 2 servings/day)

Design outcomes

Primary

MeasureTime frameDescription
Serum LipidsBaseline (Day 1,2) and Endpoint (Day 27,28) of each experimental periodTotal Cholesterol, LDL-C, HDL-C, Triglycerides
Serum non-cholesterol sterolsBaseline (Day 1,2) and Endpoint (Day 27,28) of each experimental periodLathosterol,Lanosterol,Desmosterol,Sitosterol,Campesterol,Cholestanol,
Genotype via single nucleotide polymorphism analysisBaselineSNP genotyping in genes related to cholesterol metabolism

Secondary

MeasureTime frameDescription
Cholesterol synthesis measurement by deuterium incorporationEndpoint (Day 27,28) of each experimental periodCholesterol biosynthesis will be determined as the rate of incorporation of deuterium from body water into red blood cell membrane free cholesterol over a 24 hour period (day 27 to day 28 of each period). The change in deuterium enrichment within red blood cell free cholesterol will be determined as an index of synthesis, the fractional synthesis rate (FSR) of cholesterol.
Change in cholesterol absorption due to plant sterol consumptionChange in cholesterol absorption from control period (measured over days 24-28) to plant sterol period (days 24-28)Ninety-six hours before the end of each period, participants will ingest 65 mg \[3, 4-13C\]-cholesterol. The 13C-cholesterol will be dissolved in 5 g of warmed margarine, and consumed on a slice of bread. A fasted blood sample will be taken at baseline on day 24 prior to isotope administration, as well as fasting samples on days 25, 26, 27 and 28 to monitor enrichment levels of 13C-cholesterol in plasma total cholesterol. The area under the curve of 13C-cholesterol from 0-96 hours (days 24-28) at the end of the control period will be compared to the same area under the curve at the end of the plant sterol period to determine the change in cholesterol absorption due to plant sterol consumption.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026